Guckenberger et al. analyzed longitudinal CRP levels up to 12 months in stage III NSCLC patients treated with concurrent radiochemotherapy and durvalumab consolidation in a smaller cohort of 22 patients but did not find an increase of the percentage of patients with CRP elevation > 5 mg/dl during the course of therapy and follow-up. Here, CRP is linked to non-small cell lung carcinoma.